jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
International Journal of Pharmaceutical InvestigationNOW IN
Article

In vivo evaluation of the aromatase inhibition by 4‑((1H‑imidazol‑1‑yl) methyl)‑2‑(4‑fluorophenyl)‑ 8‑phenylquinoline

Navid Sedighi1, Razieh Ghodsi1,2, Gholamreza Karimi3, Hossein Kamali4, Farzin Hadizadeh1,2★★ Corresponding author

  1. 1Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences.
  2. 2Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences.
  3. 3Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences.
  4. 4Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, IRAN.

CORRESPONDENCE

Farzin Hadizadeh

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences.

hadizadehf@mums.ac.ir

Volume 8, Issue 2 · pp. 63–68 · PUBLISHED · DOI: 10.4103/jphi.JPHI_17_18

View on IJPI original site ↗

ABSTRACT

Objective: Some of aromatase inhibitors(AIs) are Food and Drug Administration‑approved agents which are used as first‑line therapy in the treatment of endocrine‑responsive breast cancer. In this study, we aimed to develop new quinoline derivative with higher specificity and potency. Materials and Methods:The in vivo aromatase inhibition of these compounds was evaluated by measuring the inhibition of the androstenedione‑induced uterine hypertrophy. The selectivity of aromatase inhibition has been investigated by the inhibition of adrenocorticotropic hormone stimulation on the plasma concentrations of aldosterone and cortisol. Results:Letrozole (10 µg/kg) could significantly inhibit uterine hypertrophy in positive control group that received androstenedione 30 mg/kg/day. Furthermore, quinoline derivative could decrease the androstenedione‑induced uterine hypertrophy in a dose‑dependent manner. Interestingly, there was no significant difference between inhibitory potency of letrozole and quinoline derivatives. High dose of letrozole could significantly decrease the serum concentration of aldosterone and cortisol as compared to control group. On the other hand, the same doses of quinoline derivative were administered; it did not show any significant effects on the serum concentration of either aldosterone or cortisol. Conclusion: This report introduced a new compound that can be considered as new lead for further investigation to explore the more potent and more selective AIs.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Sedighi, N., Ghodsi, R., Karimi, G., Kamali, H., & Hadizadeh, F. (). In vivo evaluation of the aromatase inhibition by 4‑((1H‑imidazol‑1‑yl) methyl)‑2‑(4‑fluorophenyl)‑ 8‑phenylquinoline. International Journal of Pharmaceutical Investigation, 8(2), 63–68. https://doi.org/10.4103/jphi.JPHI_17_18